<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment with pentoxifylline is contraindicated in patients with recent cerebral or retinal hemorrhage or with active hemorrhage, in patients with coronary artery disease and in patients with impaired renal or hepatic function. Therefore, concomitant use of pentoxifylline, with agents that interfere with platelet function and with coagulation factors such as coumarin, heparin, indandione derivatives, cefotetan, cefamandole, valproic acid and plicamycin may increase the risk of bleeding. Combined use with methylxanthines and sympathomimetic agents can lead to overstimulation of the central nervous system [
 <xref rid="B133-medicina-56-00386" ref-type="bibr">133</xref>]. 
 <xref rid="medicina-56-00386-t002" ref-type="table">Table 2</xref> summarizes the effects of the antioxidants on the patients by SARS-Cov-2 infection addressed in the manuscript.
</p>
